Inmune Bio originally focused on using a dominant-negative TNF protein (DN-TNF) for cancer immunotherapy, which failed to show efficacy. Now, they’ve pivoted to neurology—repurposing the same molecule (XPro1595) for Alzheimer’s. The science behind targeting neuroinflammation is still early, and their approach lacks robust clinical validation.
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
They're in Phase 2, but data is sparse, the trial is small, and biomarkers—not clinical outcomes—are the main readout. With limited cash (~$20M as of last filing) and a high burn rate, they’ll likely need to raise before any real catalyst hits. High risk of dilution, weak scientific precedent, and a recycled failed asset = recipe for another disappointment.
Conclusion: This Alzheimer’s pivot feels like a Hail Mary. Market’s giving them credit for a turnaround that probably won’t work again ❌
トレード稼働中
Always happy to create generational wealth for my followersトレード終了: 利益確定目標に到達
Taking a victory lap on this one, you're welcome
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。